Iopofosine i-131 is a Small Molecule owned by Cellectar Biosciences, and is involved in 12 clinical trials, of which 3 were completed, 4 are ongoing, and 5 are planned.
Iopofosine I-131 (CLR-131) consists of a beta-emitting radioisotope I-131 attached to a phospholipid ether analogue with potential antineoplastic activity. CLR1404 selectively accumulates in tumor cells, thereby delivering a cytotoxic dose of radiation to cancer cells. In addition, the radioiodine moiety of this agent is resistant to de-iodination. Selective uptake and retention of the drug candidate in cancer stem cells compared with normal stem cells offers the prospect of longer lasting cancer remission. It is this "intracellular radiation" mechanism of cancer cell killing, coupled with selective delivery to a wide range of malignant tumor types that imbues HOT with broad-spectrum anti-cancer activity.
The revenue for Iopofosine i-131 is expected to reach a total of $853m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Iopofosine i-131 NPV Report.
Iopofosine i-131 Overview
Iopofosine I-131 (CLR-131) is under development for the treatment of refractory and relapsed multiple myeloma,chronic lymphocytic leukemia, Hodgkin lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma (LPL), central nervous system lymphoma, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), solid tumors,neuroblastoma, pediatric diffuse intrinsic pontine glioma, sarcomas including rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, lymphomas and malignant brain tumors, high-grade glioma, diffuse large B-cell lymphoma (DLBCL), head and neck cancer squamous cell carcinoma. It is a radiolabeled compound which is administered by intravenously. CLR-131 is comprised of PLE, 18-(p-[I-131] iodophenyl) octadacyl phosphocholine, covalently labelled with iodine-131. It was also under development for the treatment of non-small cell lung cancer, breast cancer, soft tissue sarcoma, colorectal cancer, gastric cancer, prostate cancer, ovarian cancer and esophageal cancer.
Cellectar Biosciences Overview
Cellectar Biosciences (Cellectar), is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment of cancer. The company’s proprietary technology, phospholipid drug conjugates (PDC) delivery platform develops PDCs for the treatment and diagnosis of cancer. Its lead product, CLR 131, is a small-molecule PDC, in Phase II clinical trials for the treatment of relapse or refractory multiple myeloma and B-cell lymphomas. The company is also evaluating CLR 131 in Phase I clinical trials for treatment of Pediatric patients with solid tumors, lymphomas, malignant brain tumors, head and neck cancer. Cellectar’s other products in the pipeline include CLR 1800, CLR 1900, CLR 2000, CLR 2100, CLR 2200 and CLR 12120 for solid tumors and oncology indications. The company has collaborations with Orano Med, Onconova Therapeutics, Avicenna Oncology and University of Wisconsin. Cellectar is headquartered in Florham Park, New Jersey, the US.
The operating loss of the company was US$24.1 million in FY2021, compared to an operating loss of US$15.1 million in FY2020. The net loss of the company was US$24.1 million in FY2021, compared to a net loss of US$15.1 million in FY2020.
Quick View – Iopofosine i-131
|Highest Development Stage|